Back to Feed
ClinicalTrials.gov|Clinical Trial
CD30 CAR-T Cells for Low Risk Relapsed Classical Hodgkin Lymphoma
New York Medical College
Abstract
Patients with relapsed low-risk CD30 classical Hodgkin Lymphoma will have autologous CD30 CAR T-cell manufactured. Dose escalation will be used to determine the RP2D. Following lymphodepletion, CAR T-cell will be infused. Phase: PHASE1 Status: NOT_YET_RECRUITING Conditions: Classical Hodgkin Lymphoma Interventions: CD30+ CAR T-cells; Bendamustin; Fludarabine
Keywords
Classical Hodgkin Lymphoma